Erbitux Launch Benefits From EGFR Screening; 75%-80% Of Patients Positive
Executive Summary
Screening prospective patients for expression of epidermal growth factor receptor will positively affect Erbitux' launch, ImClone said April 27
You may also be interested in...
Colorectal Cancer Drug Costs May Force Rationing – ASCO Presentation
Up-front spending on pharmaceuticals to treat colorectal cancer in the U.S. would be $7.5 bil. per year if oncologists use newly launched therapies without restrictions, Memorial-Sloan Kettering Cancer Center researcher Leonard Saltz, MD, told the American Society of Clinical Oncology annual meeting June 5 in New Orleans
Oncology Indications Can Be Cellular Targets Rather Than Organs, FDA Says
Cancer therapies can be indicated for tumors defined by cellular markers rather than conventional organ-specific targets, FDA Oncology Drug Products Division Director Richard Pazdur, MD, said during the American Society of Clinical Oncology annual meeting in New Orleans June 5
Colorectal Cancer Drug Costs May Force Rationing – ASCO Presentation
Up-front spending on pharmaceuticals to treat colorectal cancer in the U.S. would be $7.5 bil. per year if oncologists use newly launched therapies without restrictions, Memorial-Sloan Kettering Cancer Center researcher Leonard Saltz, MD, told the American Society of Clinical Oncology annual meeting June 5 in New Orleans